563 related articles for article (PubMed ID: 31076001)
1. Aberrant lipid metabolism as a therapeutic target in liver cancer.
Pope ED; Kimbrough EO; Vemireddy LP; Surapaneni PK; Copland JA; Mody K
Expert Opin Ther Targets; 2019 Jun; 23(6):473-483. PubMed ID: 31076001
[TBL] [Abstract][Full Text] [Related]
2. Metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma.
Du D; Liu C; Qin M; Zhang X; Xi T; Yuan S; Hao H; Xiong J
Acta Pharm Sin B; 2022 Feb; 12(2):558-580. PubMed ID: 35256934
[TBL] [Abstract][Full Text] [Related]
3. Acetyl-coenzyme A carboxylase alpha promotion of glucose-mediated fatty acid synthesis enhances survival of hepatocellular carcinoma in mice and patients.
Wang MD; Wu H; Fu GB; Zhang HL; Zhou X; Tang L; Dong LW; Qin CJ; Huang S; Zhao LH; Zeng M; Wu MC; Yan HX; Wang HY
Hepatology; 2016 Apr; 63(4):1272-86. PubMed ID: 26698170
[TBL] [Abstract][Full Text] [Related]
4. Targeting lipid metabolism for the treatment of anaplastic thyroid carcinoma.
von Roemeling CA; Copland JA
Expert Opin Ther Targets; 2016; 20(2):159-66. PubMed ID: 26414044
[TBL] [Abstract][Full Text] [Related]
5. Hepatocellular carcinoma stage: an almost loss of fatty acid metabolism and gain of glucose metabolic pathways dysregulation.
Balakrishnan K
Med Oncol; 2022 Oct; 39(12):247. PubMed ID: 36209296
[TBL] [Abstract][Full Text] [Related]
6. Dysregulated lipid metabolism in hepatocellular carcinoma cancer stem cells.
Bort A; Sánchez BG; de Miguel I; Mateos-Gómez PA; Diaz-Laviada I
Mol Biol Rep; 2020 Apr; 47(4):2635-2647. PubMed ID: 32125560
[TBL] [Abstract][Full Text] [Related]
7. HBx regulates fatty acid oxidation to promote hepatocellular carcinoma survival during metabolic stress.
Wang MD; Wu H; Huang S; Zhang HL; Qin CJ; Zhao LH; Fu GB; Zhou X; Wang XM; Tang L; Wen W; Yang W; Tang SH; Cao D; Guo LN; Zeng M; Wu MC; Yan HX; Wang HY
Oncotarget; 2016 Feb; 7(6):6711-26. PubMed ID: 26744319
[TBL] [Abstract][Full Text] [Related]
8. Role of lipids in pathophysiology, diagnosis and therapy of hepatocellular carcinoma.
Buechler C; Aslanidis C
Biochim Biophys Acta Mol Cell Biol Lipids; 2020 May; 1865(5):158658. PubMed ID: 32058031
[TBL] [Abstract][Full Text] [Related]
9. Targeting lipid metabolism in the treatment of ovarian cancer.
Chaudhry S; Thomas SN; Simmons GE
Oncotarget; 2022; 13():768-783. PubMed ID: 35634242
[TBL] [Abstract][Full Text] [Related]
10. The importance of acetyl coenzyme A synthetase for 11C-acetate uptake and cell survival in hepatocellular carcinoma.
Yun M; Bang SH; Kim JW; Park JY; Kim KS; Lee JD
J Nucl Med; 2009 Aug; 50(8):1222-8. PubMed ID: 19617323
[TBL] [Abstract][Full Text] [Related]
11. Aberrant lipid metabolism in hepatocellular carcinoma cells as well as immune microenvironment: A review.
Hu B; Lin JZ; Yang XB; Sang XT
Cell Prolif; 2020 Mar; 53(3):e12772. PubMed ID: 32003505
[TBL] [Abstract][Full Text] [Related]
12. Increased FNDC5/Irisin expression in human hepatocellular carcinoma.
Gaggini M; Cabiati M; Del Turco S; Navarra T; De Simone P; Filipponi F; Del Ry S; Gastaldelli A; Basta G
Peptides; 2017 Feb; 88():62-66. PubMed ID: 28012856
[TBL] [Abstract][Full Text] [Related]
13. BTG1 ameliorates liver steatosis by decreasing stearoyl-CoA desaturase 1 (SCD1) abundance and altering hepatic lipid metabolism.
Xiao F; Deng J; Guo Y; Niu Y; Yuan F; Yu J; Chen S; Guo F
Sci Signal; 2016 May; 9(428):ra50. PubMed ID: 27188441
[TBL] [Abstract][Full Text] [Related]
14. Aberrant lipid metabolism in cancer cells - the role of oncolipid-activated signaling.
Ray U; Roy SS
FEBS J; 2018 Feb; 285(3):432-443. PubMed ID: 28971574
[TBL] [Abstract][Full Text] [Related]
15. Fatty acid metabolism reprogramming in ccRCC: mechanisms and potential targets.
Tan SK; Hougen HY; Merchan JR; Gonzalgo ML; Welford SM
Nat Rev Urol; 2023 Jan; 20(1):48-60. PubMed ID: 36192502
[TBL] [Abstract][Full Text] [Related]
16. Key Molecules of Fatty Acid Metabolism in Gastric Cancer.
Li C; Zhang L; Qiu Z; Deng W; Wang W
Biomolecules; 2022 May; 12(5):. PubMed ID: 35625633
[TBL] [Abstract][Full Text] [Related]
17. Hepatic lipid composition and stearoyl-coenzyme A desaturase 1 mRNA expression can be estimated from plasma VLDL fatty acid ratios.
Peter A; Cegan A; Wagner S; Lehmann R; Stefan N; Königsrainer A; Königsrainer I; Häring HU; Schleicher E
Clin Chem; 2009 Dec; 55(12):2113-20. PubMed ID: 19850634
[TBL] [Abstract][Full Text] [Related]
18. Targeting ZBP-89 for the treatment of hepatocellular carcinoma.
Wang N; Wang S; Yang SL; Liu LP; Li MY; Lai PBS; Chen GG
Expert Opin Ther Targets; 2018 Oct; 22(10):817-822. PubMed ID: 30142986
[TBL] [Abstract][Full Text] [Related]
19. Polymorphisms in genes of the de novo lipogenesis pathway and overall survival of hepatocellular carcinoma patients undergoing transarterial chemoembolization.
Wu YS; Bao DK; Dai JY; Chen C; Zhang HX; Yang Y; Xing JL; Huang XJ; Wan SG
Asian Pac J Cancer Prev; 2015; 16(3):1051-6. PubMed ID: 25735330
[TBL] [Abstract][Full Text] [Related]
20. Differential requirement for de novo lipogenesis in cholangiocarcinoma and hepatocellular carcinoma of mice and humans.
Li L; Che L; Tharp KM; Park HM; Pilo MG; Cao D; Cigliano A; Latte G; Xu Z; Ribback S; Dombrowski F; Evert M; Gores GJ; Stahl A; Calvisi DF; Chen X
Hepatology; 2016 Jun; 63(6):1900-13. PubMed ID: 26910791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
